Great Point Partners

iXCells Biotechnologies is a global research and development organization that specializes in patient-derived stem cells and primary cells. The company provides a range of cell biology and technology services aimed at supporting the development of therapeutic drugs and disease models. With a strong emphasis on preclinical drug discovery, iXCells focuses on creating disease-relevant cellular models that assist clients in the academic, biotech, and pharmaceutical sectors. By offering advanced technologies and services, iXCells Biotechnologies plays a crucial role in facilitating research and innovation in the life sciences industry.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Operater of a full-service public relations, marketing, and advocacy agency synchronizes insights and executes ideas. The company's offerings include earned media, advocacy relations, public affairs, stakeholder engagement, and digital and creative services, helping clients design health campaigns that drive change and deliver measurable results.

Designer and manufacturer of therapeutic and diagnostic medical devices serving clients of all sizes ranging from startups seeking seed funding to established Fortune 500 companies. The company specializes in cybersecurity, device development, test systems and medical device manufacturing and offers expertise in software, usability, cybersecurity, electrical and mechanical development for medical equipment, thereby enabling clients to transform their IP into a safe and secure product that will change lives for a better world.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.

Bionova Scientific, Inc. is a biologics contract development and manufacturing organization based in Fremont, California, founded by a group of biopharmaceutical specialists in 2014. The company specializes in providing comprehensive services for biologics development and manufacturing, including early-stage research material generation, cell line development for new biological entities and biosimilars, and process development. Bionova Scientific supports the production of various biomolecules such as glycoproteins, monoclonal antibodies, and enzymes, focusing on optimizing expression systems and scaling up cell culture processes. Their expertise also extends to technology transfer and ensuring that biologic therapies are efficiently developed and brought to market for drug development companies.

Axiom Real-Time Metrics Inc. develops an eClinical software that provides solutions and services to small and medium life sciences organizations. The company’s software focuses on electronic data capture ("EDC"), data management ("DM"), clinical trial management systems ("CTMS"), randomization ("IWRS"), electronic patient reported outcomes ("ePRO"), and other technology and service solutions for biotechnology and pharmaceutical sponsors conducting clinical trials. Its services include eClinical management, biostats, pharmacovigilance, and training. The company was founded in 2001 and is based in Toronto, Canada.

Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.

CSM solves complex clinical trial supply problems for biotech and pharmaceutical companies such as limited drug supply, time constraints and mid-study changes. They offer a unique blend of traditional and innovative services that can significantly shorten timelines, reduce costs and improve outcomes for clinical studies.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.

Bovie Medical Corporation manufactures digital electrosurgical generators and accessories for the operating room and surgicenter. It is also a producer of battery-operated cauteries in the world. Its technology is a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision and minimal invasiveness.

HRAA interprets data to ensure that healthcare is efficient and effective for everyone by pulling medical data together to create a predictive window to understand cost and revenues looking back and going forward. Founded in 2001 and based out of Plantation, FL, HRAA combines years of industry expertise with best-in-breed technology to create market leading business intelligence products and consulting services to ensure hospitals are reimbursed for every pill they prescribe, every procedure they perform and every test they administer. HRAA both trains and supplies the high tech workforce to hospitals to generate the predictive data used by the whole healthcare system and offers a full suite of solutions needed to keep up with the ever-changing healthcare industry including data analytics software, business intelligence technology, medical coding, auditing, education, revenue cycle consulting, and ICD-10 transition solutions.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute and chronic liver diseases, addressing significant unmet medical needs. The company's lead product, OCR-002, is an ammonia scavenger available in both intravenous and oral formulations, specifically targeting hyperammonemia. Ocera recently completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. The company is planning to engage with the FDA to explore potential development pathways for its intravenous program later this year.

iVantage Health Analytics, Inc. specializes in healthcare analytics and business intelligence solutions tailored for the healthcare industry. The company offers a range of products, including the Hospital Strength INDEX, which evaluates U.S. acute-care hospitals based on financial and performance metrics. Its VantagePoints platform delivers population health analytics and consulting services aimed at enhancing clinical performance and optimizing reimbursement. Additionally, iVantage provides tools such as iBenchmarks, which helps hospitals identify operational and clinical improvement opportunities, and the INCONTROL Contract Optimizer, which assesses market dynamics affecting hospital operations. Other offerings include EnvisionHIT for healthcare business planning, iVantage Market Intelligence for strategic insights, and iVantage Performance Manager for cloud-based performance management. Founded in 2006 and headquartered in Portland, Maine, iVantage operates additional offices in several states and has been a subsidiary of The Chartis Group since 2015.

Connecture, Inc. provides Web-based sales, service, and process automation solutions to the private Medicare insurance industry, including Medicare Advantage and Prescription Drug Plans. The company offers the PlanCompare and DrugCompare product suites, via SaaS installations for Medicare carriers and PBMs. It also provides on-site software installation and integration, and managed hosting solutions, as well as customer support services for health insurance companies. Connecture, Inc. divested its non-Medicare insurance products and now focuses exclusively on Medicare insurers and PBMs, originally served by acquired company DRX. The company was acquired by Harris Computer Systems in October, 2019 and is headquartered in Milwaukee, Wisconsin.

Aris Radiology specializes in delivering professional radiology services to hospitals, surgeons, and healthcare institutions. As a Joint Commission certified provider, Aris collaborates with local hospitals and radiology groups to offer a comprehensive solution that includes high-quality radiologists, around-the-clock subspecialty coverage, and operational support. The company provides on-site radiology management, teleradiology services, patient billing, and recruitment of radiologists, all aimed at enhancing the quality, speed, and accuracy of diagnostics while prioritizing patient safety. By offering a broad range of services, Aris ensures cost-effective patient care for healthcare payors and institutions.

WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.

Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating and commercializing innovative treatments for diabetes. The company specializes in applying its proprietary formulation technologies to enhance existing drugs, primarily targeting rapid-acting mealtime insulin for patients with Type I and Type II diabetes through its product candidate, Linjeta. In addition to Linjeta, Biodel is exploring earlier-stage candidates, which include follow-on rapid-acting insulins, a sublingual tablet formulation of insulin known as VIAtab, a range of basal insulins, and a glucagon formulation. Through its proprietary VIAdel technology, Biodel studies the interactions between peptide hormones and small molecules to advance its product development efforts.

American Surgical Professionals is a provider of professional surgical assistant services to hospitals, clinics, surgeons and patients. American Surgical Professionals offers custom tailored solutions to perioperative staffing situations. These include providing surgical specialists on an outsourced, as needed or contract basis.

Cytovance Biologics is a full service CDMO specializing in cGMP production of therapeutic proteins & antibodies from mammalian cell culture (CHO), microbial fermentation (Ecoli), and transgenic processes. We offer cell line development, process development services, purification development, stability testing, and more from our FDA inspected, Oklahoma City state-of-the-art facilities.

Solta Medical, Inc. specializes in designing, developing, manufacturing, and marketing energy-based medical devices focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and contouring, and the Fraxel series of systems that treat various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. Their devices incorporate advanced technology with handpieces, user-friendly consoles, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and general practitioners, and distributes its products through a direct sales force and a network of international distributors. Founded in 1995 and headquartered in Hayward, California, the company was previously known as Thermage, Inc. before rebranding in 2009.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

Solta Medical, Inc. specializes in designing, developing, manufacturing, and marketing energy-based medical devices focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and contouring, and the Fraxel series of systems that treat various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. Their devices incorporate advanced technology with handpieces, user-friendly consoles, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and general practitioners, and distributes its products through a direct sales force and a network of international distributors. Founded in 1995 and headquartered in Hayward, California, the company was previously known as Thermage, Inc. before rebranding in 2009.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Biotronic will continue to lead the intraoperative neural monitoring industry with our breadth of services, patient-centric focus, clinical research & education, geographic concentration and reach, and financial performance. In pursuit of our mission & vision, Biotronic has assembled the clinical expertise and organizational capabilities needed to provide excellence in care and prompt, reliable service with managed cost efficiency. As experts in this specialty, we take pride in partnering with hospitals and surgeons to obtain and analyze critical information during selective surgeries which place neural structures at risk. The information we provide allows surgeons to intervene immediately to mitigate problems that may otherwise go undetected until after completion of the surgery. We help you improve your quality and do so within a cost-effective partnership.

As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

Forbes Medi-Tech Inc. is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products.